A Phase I Dose Escalation Study to Evaluate Maximum Tolerated Dose (MTD), Pharmacokinetics (PK), and Safety of BT062 in Subjects With Relapsed or Relapsed/Refractory Multiple Myeloma.
Phase of Trial: Phase I
Latest Information Update: 07 Jan 2013
At a glance
- Drugs Indatuximab ravtansine (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 16 Dec 2011 Planned end date changed from 1 Dec 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.
- 12 Dec 2011 Preliminary results reported at the 53rd Annual Meeting and Exposition of the American Society of Hematology.
- 07 Jun 2011 Planned End Date changed from 1 Jan 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.